兰瑞肽对神经内分泌肿瘤患者68Ga-DOTATATE摄取的前瞻性自身对照评估
该前瞻性自身对照研究纳入34例正在接受兰瑞肽治疗至少4个月的转移性或不可切除神经内分泌肿瘤患者,在兰瑞肽注射前1天和注射后1天分别行68Ga-DOTATATE PET/CT,比较肿瘤病灶和正常组织的摄取变化。结果显示注射兰瑞肽后肿瘤摄取显著增加,肝、脾、甲状腺摄取显著降低,肿瘤/肝比值升高,但差异较小且被认为无临床相关性。作者认为在68Ga-DOTATATE PET前数周停用兰瑞肽注射是不必要的。
要点
- 兰瑞肽注射后肿瘤68Ga-DOTATATE摄取显著增加,而肝、脾、甲状腺摄取显著降低。
- 肿瘤/肝比值因此升高,但差异小且被认为无临床相关性。
- 作者认为68Ga-DOTATATE PET前停用兰瑞肽数周不必要,且不影响核医学显像结果。
核心结论
- 兰瑞肽注射不会导致肿瘤对68Ga-DOTATATE的摄取降低,反而使肿瘤摄取增加、正常器官摄取降低,肿瘤/肝比值升高,但这些差异较小且被认为无临床相关性。
- 这些结果强烈提示在68Ga-DOTATATE PET检查前数周停用兰瑞肽注射是不必要的,且不影响核医学显像结果。
研究设计与样本
- 前瞻性自身对照研究,纳入34例转移性和/或不可切除且正在接受兰瑞肽治疗至少4个月的神经内分泌肿瘤患者。
- 每例患者在兰瑞肽注射前1天和注射后1天分别行68Ga-DOTATATE PET/CT,评估肿瘤病灶和正常组织的SUVmax、mean、peak,由两名盲法核医学科医生进行视觉分析,采用配对t检验比较两次扫描差异。
- 34例中31例可分析,共测量190个肿瘤病灶。
主要发现
- 兰瑞肽注射后肿瘤病灶68Ga-DOTATATE摄取显著增加。
- 兰瑞肽注射后肝、脾和甲状腺的68Ga-DOTATATE摄取显著降低,导致肿瘤/肝比值升高。
- 上述差异较小且被认为无临床相关性。
临床怎么用
- 作者认为,基于上述结果,在68Ga-DOTATATE PET检查前数周停用兰瑞肽注射是不必要的,且不影响核医学显像结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Somatostatin receptor imaging with PET is the standard of care for patients with a neuroendocrine tumour (NET). Since therapy and imaging with somatostatin analogues utilize the same receptor, current guidelines recommend withdrawing long-acting somatostatin analogues for 3-4 weeks prior to somatostatin receptor PET imaging. The aim of this study is to prospectively assess the effect of lanreotide use on the uptake of 68Ga-DOTATATE intra-individually 1 day prior to and 1 day post injection of lanreotide. METHODS: Thirty-four patients with metastatic and/or unresectable NET and currently on lanreotide therapy for at least 4 months were included in the study. A 68Ga-DOTATATE PET/CT scan was performed on the day before and the day after lanreotide injection. In each patient 68Ga-DOTATATE uptake (SUVmax, mean, peak) was assessed in both tumour lesions and normal tissue. All scans were assessed by two blinded nuclear medicine physicians for visual analysis. Paired T-tests were performed to determine the differences between the scans. RESULTS: Of the 34 patients included, 31 were available for analyses in which 190 tumour lesions were measured. Uptake of 68Ga-DOTATATE in tumour lesions was increased significantly after lanreotide, but decreased significantly in the liver, spleen, and thyroid gland resulting in a higher tumour-to-liver ratio. CONCLUSION: Lanreotide injection prior to 68Ga-DOTATATE PET/CT does not result in decreased tumour uptake. In contrast, tumour uptake was increased, whereas the uptake in normal organs is decreased, leading to an increased tumour-to-liver ratio. However, these differences were small and not deemed clinically relevant. These results strongly suggest that discontinuation of lanreotide injections in the weeks prior to 68Ga-DOTATATE PET examinations is unnecessary and does not compromise nuclear medicine imaging results.
引用
- Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MWJ, et al. Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation. Eur J Nucl Med Mol Imaging. 2018. PMID: 30097670. doi:10.1007/s00259-018-4117-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。